ARGX vs. BNTX, NBIX, BIIB, TECH, QGEN, RGEN, EXEL, PCVX, RVMD, and MRNA
Should you be buying argenx stock or one of its competitors? The main competitors of argenx include BioNTech (BNTX), Neurocrine Biosciences (NBIX), Biogen (BIIB), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Exelixis (EXEL), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Moderna (MRNA). These companies are all part of the "biological products, except diagnostic" industry.
argenx (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.
BioNTech has a net margin of 24.26% compared to argenx's net margin of -23.26%. BioNTech's return on equity of 4.60% beat argenx's return on equity.
In the previous week, BioNTech had 27 more articles in the media than argenx. MarketBeat recorded 36 mentions for BioNTech and 9 mentions for argenx. argenx's average media sentiment score of 0.43 beat BioNTech's score of 0.02 indicating that argenx is being referred to more favorably in the media.
BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
60.3% of argenx shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.4% of argenx shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
argenx has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
argenx presently has a consensus price target of $528.16, indicating a potential upside of 33.91%. BioNTech has a consensus price target of $118.82, indicating a potential upside of 31.63%. Given argenx's stronger consensus rating and higher possible upside, equities analysts plainly believe argenx is more favorable than BioNTech.
argenx received 483 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.75% of users gave argenx an outperform vote while only 42.54% of users gave BioNTech an outperform vote.
Summary
argenx beats BioNTech on 10 of the 19 factors compared between the two stocks.
Get argenx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
